Josh is a Co-Founder and Managing Partner of Lux Capital, focusing on investments in nanotechnology, semiconductors and life sciences. Josh manages Lux Capital's investments in Nanosys and Cambrios, and serves on the Board of Directors of Crystal IS and Lux Research. Before forming Lux Capital, he worked in Salomon Smith Barney's Investment Banking group, where his experience included a $4 billion hotel merger and a defense against an unsolicited LBO. Josh has also worked in capital markets while at Merrill Lynch on its Financial Futures & Options/Government Strategy desk and at Prudential Securities in its Municipal Finance department.
Prior to venturing into the financial world, Josh conducted and published cutting-edge AIDS/immunopathology research in Cell Vision and The Journal of Leukocyte Biology, leading medical/immunology journals. Josh graduated with distinction from Cornell University with a B.S. in Economics and Finance. He has been an invited guest speaker, lecturer, and panelist on nanotechnology for CNBC, CNN, Harvard, Yale, Wharton, Columbia, Cornell, Merrill Lynch, Credit Suisse First Boston, Capitol Hill, government labs, and officials in France, Canada, UK, Spain, Singapore, and Germany. Widely recognized as one of the preeminent minds in nanotechnology and finance, Josh has been invited by the White House and Canadian Government to advise government organizations on funding strategies.
Josh is a co-founder of The NanoBusiness Alliance, a columnist with Forbes Magazine and Editor of the monthly Forbes/Wolfe Emerging Tech Report.
Josh's weekly essays & insights: http://www.forbeswolfe.com/
Lux Capital Management is a research-driven investment firm focused on founding, seed and early stage investments in the physical and life sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Our investment team has built over 20 companies from scratch. Lux's investment strategy ensures our portfolio companies are better connected, have deeper insight, and command industry leadership faster than their competitors.
The Lux team is recognized internationally as pioneers and thought-leaders in early stage venture capital. Our team has a successful track record of building, investing in, and adding highly strategic value to leading emerging technology companies started at more than 40 leading academic centers and government labs including MIT, Harvard, Stanford, Caltech, Columbia, Cornell, Texas, UCLA, UC Berkeley, Washington University, and Lawrence Livermore National Labs. We've been invited by the President to the Oval Office, appear frequently on CNBC, CNN and Fox News, and are regularly cited in The Economist, Forbes, Business Week, Barron's, and other leading financial and technology publications.
Lux has co-invested with leading private equity firms and multinational corporations. Some of Lux's investment partners include Goldman Sachs, Credit Suisse, Sequoia Capital, Venrock Associates, Polaris Venture Partners, Intel, Motorola, Genentech, and Medtronic.
Lux launched strategic portfolio companies in market research/business intelligence (Lux Research), media (Forbes/Wolfe Emerging Tech Report) and public policy (NanoBusiness Alliance). These entities provide us with multiple edges over other venture capital funds for sourcing deals, adding value to the entrepreneurs and companies we invest in, and exiting investments.